ESPR vs. RDUS, OMER, PAHC, CARA, CALT, VRNA, EWTX, EVO, NAMS, and AVDL
Should you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Radius Recycling (RDUS), Omeros (OMER), Phibro Animal Health (PAHC), Cara Therapeutics (CARA), Calliditas Therapeutics AB (publ) (CALT), Verona Pharma (VRNA), Edgewise Therapeutics (EWTX), Evotec (EVO), NewAmsterdam Pharma (NAMS), and Avadel Pharmaceuticals (AVDL).
Radius Recycling (NASDAQ:RDUS) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.
In the previous week, Radius Recycling had 4 more articles in the media than Esperion Therapeutics. MarketBeat recorded 9 mentions for Radius Recycling and 5 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 0.64 beat Radius Recycling's score of -0.02 indicating that Radius Recycling is being referred to more favorably in the media.
Esperion Therapeutics has a consensus price target of $8.83, indicating a potential upside of 263.51%. Given Radius Recycling's stronger consensus rating and higher possible upside, analysts clearly believe Esperion Therapeutics is more favorable than Radius Recycling.
Radius Recycling has higher revenue and earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Radius Recycling, indicating that it is currently the more affordable of the two stocks.
Radius Recycling has a net margin of -10.28% compared to Radius Recycling's net margin of -37.65%. Radius Recycling's return on equity of 0.00% beat Esperion Therapeutics' return on equity.
78.1% of Radius Recycling shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 5.7% of Radius Recycling shares are held by insiders. Comparatively, 1.0% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Esperion Therapeutics received 260 more outperform votes than Radius Recycling when rated by MarketBeat users. Likewise, 69.91% of users gave Esperion Therapeutics an outperform vote while only 54.17% of users gave Radius Recycling an outperform vote.
Radius Recycling has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.
Summary
Radius Recycling beats Esperion Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Esperion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Esperion Therapeutics Competitors List
Related Companies and Tools
